Google
PTGX — PROTAGONIST THERAPEUTICS INC (Healthcare >> Biotechnology)
PTGX FAQ
What is PTGX's P/E ratio?
PROTAGONIST THERAPEUTICS INC (PTGX) currently trades at a P/E ratio of 1,869.61.
What is PTGX's ROE?
PROTAGONIST THERAPEUTICS INC reports a Return on Equity (ROE) of -17.50%.
What is PTGX's dividend yield?
PROTAGONIST THERAPEUTICS INC offers a dividend yield of 0.00%.
What is PTGX's Deepscope Quality Score?
Deepscope rates PTGX's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy PTGX?
Deepscope's AI Timing Score for PTGX is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does PTGX belong to?
PROTAGONIST THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 105.77
Price
-0.10
(-0.09%)
Day Change
|
|
|---|
PTGX, ファンダメンタルスコアはnot good ( ファンダメンタル = 15) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/Eが高い。割高銘柄。
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 105.77 |
| PBV / Sector |
10.79 / 4.79
|
| Earning Per Share | -1.72 |
| PE / Sector |
1,869.61 / 17.89
GREAT
|
| PEG or PE/Growth / Sector |
-9.39 / 0.56
|
| Average 1M Daily Value |
55.70 M
|
| Average 1W Daily Value |
75.77 M
|
| Timing Factors |
|
71% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-11 09:55:20 |
| Symbol | PTGX |
| Name | PROTAGONIST THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 64.31 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 7,072.73 / 8,963.32 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 7707 Gateway Boulevard, Newark, CA, United States, 94560
Phone: 510 474 0170
Website: https://www.protagonist-inc.com
Employees: 131
Sector: Healthcare >> Biotechnology
Description: Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
